TORONTO and WINNIPEG, Aug. 13 /CNW/ - Cangene Corporation today reports
that it has met all the regulatory and manufacturing requirements for the
"Usable Product" milestone on contracts with the U.S. government for products
to treat botulism and inhalational anthrax. The contracts, the largest in
Cangene history, were signed last year and are managed by the U.S. Biomedical
Advanced Research and Development Authority ("BARDA") within the Department of
Health and Human Services ("HHS"). The Usable Product designation means the
Company has met specific regulatory and manufacturing requirements that allow
it to deliver the products to the U.S. Strategic National Stockpile and begin
invoicing once delivery has been accepted.
